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vascular disease or diabetes) should have LDL-C levels
<2.5mmol/L. Canadians at very high risk and with high
blood lipid levels would require an LDL-C reduction of
at least 47% to achieve treatment goal. Of marketed
statins, only moderate to high doses of atorvastatin (20,
40 and 80mg), simvastatin (80mg) or lovastatin (80mg)
could achieve the LDL-C reduction required by Canadian
guidelines. In contrast, a new lipid-lowering agent (rosu-
vastatin) could achieve a 47% LDL-C reduction at the 
10mg dose. CONCLUSIONS: A signiﬁcant proportion 
of Canadians should receive aggressive lipid-lowering
therapy, which can only be achieved with higher doses of
currently marketed statins to achieve Canadian treatment
goals. Newer statins such as rosuvastatin would assist in
achieving the updated treatment goals. By achieving these
targets at lower doses, rosuvastatin can improve ease and
success of management of hyperlipidemia.
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OBJECTIVE: The aim of this study was to evaluate inter-
vention of drug treatment to elderly patients with car-
diovascular diseases living in nursing homes and assess
the effect of this intervention. METHOD: Eighty patients
living in nursing homes in the County of Stockholm were
randomized into 2 groups, 43 to the intervention group
(average age 87 years) and 37 to the control group
(average age 85 years). Patients included had diagnoses
of heart failure, post myocardial infarction or cardiac
valvular disease. Patients with drug treatment related 
to these diagnoses were also included. At a ﬁrst visit a
research nurse interviewed each patient to collect data of
symptoms and health-related quality of life. The drug
therapy was recorded. After reviewing medication, spe-
cialists in clinical pharmacology and cardiology suggested
changes in the cardiovascular drug therapy to the respon-
sible physician. At each following visit the current drug
therapies as well as data of symptoms and health-related
quality of life were recorded. RESULTS: The outcome
was measured as scores of symptoms. Changes of total
Health Index, ADL scores and deaths were recorded 
as well. The patients in the intervention group initially
consumed 9.8 drugs on the average. For the control 
group this ﬁgure was 9.2 drugs. A change of cardiovas-
cular drug therapy was suggested for 40 patients. Thirty-
two changes in 19 patients were carried out, mainly
regarding furosemide and potassium. Suggestions to ini-
tiate treatment with ACE-inhibitors were never followed.
There were no signiﬁcant changes in the scores of symp-
toms, total Health Index or ADL scores. CONCLU-
SIONS: The self-reported symptoms for each patient were
helpful as a guide for the specialists to evaluate the drug
therapy. The intervention resulted in reduction of drug
use in half of the patients in the intervention group
without any negative effects on health of symptoms.
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OBJECTIVES: U.S. studies using varying methodologies
have reported different estimates for the indirect cost per
person with IBD. Our analysis contributes to this litera-
ture, by using the 1999 sample of the National Health
Interview Survey (NHIS) to estimate the employment
effect of Inﬂammatory Bowel Disease (IBD) in the United
States. METHODS: Our predictive analysis adapts the
theory of labor supply to a health context. A weighted
logistic regression model was used to estimate the odds
ratio (OR) of being out of the labor force as determined
by predictive variables including having been diagnosed
with IBD, with or without symptoms. Controls included
demographic variables and health status indicators. For
those people in the labor force, a second analysis was 
performed to determine whether an individual worked
throughout the entire duration of the past 12 months or
less than 12 months. SUDAAN 8.0 was used to generate
population estimates, systematically correcting for survey
design. RESULTS: Thirty-one and one-half percent of
IBD patients who had experienced symptoms in the past
12 months reported being out of the labor force with OR
= 2.07. We estimated the excess in the non-participation
rate attributable to IBD with symptoms in the past 12
months in the United States to be 11.7%. Based on this,
the indirect cost of non-participation attributable to IBD
in 1998 was $3.5 billion US dollars or $4973 per person
with IBD and symptoms. According to the second
weighted logistic regression, having IBD had no associa-
tion with the duration of work, for those who are in the
labor force. Consequently, the indirect cost of IBD
reported can be interpreted as the indirect cost of IBD
associated with employment losses. CONCLUSIONS: By
using directly observed data in our analysis, this method
of estimation can be used to predict the overall paid-
employment burden of IBD.
